



Contact:

David Waldman or Justyna Gudaszevska

Crescendo Communications, LLC

Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)

Tel: +48 693 354 580

**Milestone Medical Commences Sales of CompuFlo® Instruments / CathCheck™ Verification System Disposables within the UTMB Health Clear Lake Campus Hospital**

*Agreement represents second hospital within the UTMB Health network*

**Roseland, NJ., July 7, 2021 – Milestone Medical Inc. (WAR: MMD, “the Company”)**, today announced that today reported that the University of Texas Medical Branch (UTMB) Health Clear Lake Campus Hospital has begun use of the [CompuFlo Epidural Instrument](#). UTMB is an institution of the University of Texas System and agency of the State of Texas. UTMB is a major academic health sciences center of global influence, with medical, nursing, health professions and graduate biomedical schools; a world-renowned research enterprise; and a growing, comprehensive health system with hospitals on four campuses. As previously announced, the Company had begun selling CompuFlo disposables to the UTMB Health Galveston Campus Hospital.

Arjan Haverhals, CEO of Milestone Medical, stated: “I am very pleased to announce that UTMB Health has expanded its use of the CompuFlo Epidural Instrument, including its consumables to its Clear Lake Campus Hospital. This expansion follows successful use of the instrument and disposables at the Galveston Campus Hospital and is strong validation of the favorable response to Milestone Scientific’s technology by leading anesthesiologists. At the same time, our new sales force initiatives are taking hold, and interest in the technology is growing.”

**About Milestone Medical Inc.**

Milestone Medical, Inc. (WAR:MMD) has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**About Milestone Scientific Inc.**

[Milestone Scientific Inc.](#) (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections

precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing Technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information, please visit our website: [www.milestonescientific.com](http://www.milestonescientific.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

###